Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 24, 2021

USFDA accepts priority review for Pfizer’s TicoVac

Pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for priority review for TicoVac, a tick-borne encephalitis (TBE) vaccine.

Pfizer said that TicoVac will help reduce the risk of TBE virus for adults and children who are travelling to or living in endemic areas. (Credit: Coolcaesar/Wikipedia.org.)